Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: Application to vaccine development

Advanced Drug Delivery Reviews

Volumn 52, Issue 3, 2001, Pages 177-186

  Kunisawa, Jun ^a   Nakagawa, Shinsaku ^a   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer chemotherapy; Fusogenic liposome; Gene therapy; Mucosal vaccine; Sendai virus; Tumor vaccine

Indexed keywords

ANTIGENS; DRUG THERAPY; ENCAPSULATION; GENES; ULTRAVIOLET RADIATION; VACCINES;

DELIVERY RATES;

CONTROLLED DRUG DELIVERY;

CANCER VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOSOME; POLYSACCHARIDE; VACCINE;

CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INTRACELLULAR MEMBRANES; LIPOSOMES; SENDAI VIRUS; VACCINES;

EID: 0035915050     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00214-9     Document Type: Review

References (53)

1. Delivery systems for molecular vaccination
2. Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy
3. Gene delivery systems using the Sendai virus
4. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors
5. Efficient gene transfer into mammalian cells using fusogenic liposome
6. Gene transfer vectors based on Sendai virus
7. The mucosal immune system
8. Strategies for mucosal vaccine development
9. New approaches to mucosal immunization
10. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses
11. Nasal delivery of vaccines
12. New approaches to antigen delivery
13. Determinants of organ tropism of Sendai virus
14. Efficient gene transfer to airway epithelium using recombinant Sendai virus
15. Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants
16. Sendai virion structure and its interaction with cellular membranes
17. Sendai virus
18. Trypsin action on the growth of Sendai virus in tissue culture cells. 3. Structural difference of Sendai viruses grown in eggs and tissue culture cells
19. Identification and characterization of cell lines with a defect in a post-adsorption stage of Sendai virus-mediated membrane fusion
20. Efficient introduction of contents of liposomes into cells using HVJ (Sendai virus)
21. Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method
22. Fusion of sendai virus with liposome depends on only F protein, but not HN protein
23. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway
24. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
25. Target-cell specificity of fusogenic liposomes: Membrane fusion-mediated macromolecule delivery into human blood mononuclear cells
26. Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth
27. Current concepts in cancer vaccine strategies
28. Design and evaluation of antigen-specific vaccination strategies against cancer
29. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry
30. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins
31. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins
32. Novel adjuvants and vaccine delivery systems
33. Sendai virus fusion protein-mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system
34. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains
35. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins
36. A novel vaccine delivery system using immunopotentiating fusogenic liposomes
37. Development of oral vaccines for human use
38. Advances in vaccine adjuvants
39. Recent advances in mucosal vaccine development
40. Mucosal delivery of vaccines
41. Optimal induction of upper respiratory tract immunity to reovirus 1/L by combined upper and lower respiratory tract inoculation
42. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: Fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production
43. Nasal immune system: Distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively
44. Nasal-associated lymphoid tissue: Phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site
45. The Waldeyer's ring
46. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system
47. Antigen-specific IgA response of NALT and cervical lymph node cells in antigen-primed rats
48. Vaccines for mucosal immunity to combat emerging infectious diseases
49. The NALT immunity for the development of mucosal vaccine
50. Lectin binding patterns in rat nasal-associated lymphoid tissue (NALT) and the influence of various types of lectin on particle uptake in NALT
51. Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats
52. M cells as ports of entry for enteroinvasive pathogens: Mechanisms of interaction, consequences for the disease process
53. The role of M cells in mucosal immunity